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Abstract
Background: Tissue factor pathway inhibitor-2 (TFPI-2) is a matrix-associated Kunitz inhibitor
that inhibits plasmin and trypsin-mediated activation of zymogen matrix metalloproteinases
involved in tumor progression, invasion and metastasis. Here, we have investigated the mechanism
of DNA methylation on the repression of TFPI-2 in breast cancer cell lines.
Results: We found that both protein and mRNA of TFPI-2 could not be detected in highly invasive
breast cancer cell line MDA-MB-435. To further investigate the mechanism of TFPI-2 repression in
breast cancer cells, 1.5 Kb TFPI-2 promoter was cloned, and several genetic variations were
detected, but the promoter luciferase activities were not affected by the point mutation in the
promoter region and the phenomena was further supported by deleted mutation. Scan mutation
and informatics analysis identified a potential KLF6 binding site in TFPI-2 promoter. It was revealed,
by bisulfite modified sequence, that the CpG island in TFPI-2 promoter region was
hypermethylated in MDA-MB-435. Finally, using EMSA and ChIP assay, we demonstrated that the
CpG methylation in the binding site of KLF-6 diminished the binding of KLF6 to TFPI-2 promoter.
Conclusion:  In this study, we found that the CpG islands in TFPI-2 promoter was
hypermethylated in highly invasive breast cancer cell line, and DNA methylation in the entire
promoter region caused TFPI-2 repression by inducing inactive chromatin structure and decreasing
KLF6 binding to its DNA binding sequence.
Background
Human tissue factor pathway inhibitor-2 (TFPI-2) is a
kunitz-type serine proteinase inhibitor synthesized and
secreted into extrocelluar matrix (ECM) by endothelial
cells, smooth muscle cells, fibroblasts, keratinocytes and
urothelium [1,2]. TFPI-2 readily inhibits trypsin, plasmin,
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chymotrypsin, cathepsin G, plasma kallikrein and the fac-
tor VIIa-tissue factor complex, but not urokinasetype plas-
minogen activator (uPA), tissue-type plasminogen
activator (tPA) or thrombin [3,4]. It had already been
reported that the expression of TFPI-2 was down regulated
in several invasive tumor cell lines, including choriocarci-
noma, glioma, prostate cancer, melanoma and fibrosar-
coma, moreover ectopic expression of this gene inhibits
tumors growth and metastasis in vivo by regulating peri-
cellular ECM remodeling and angiogenesis [5-10]. Never-
theless, the mechanisms that alter/modify the expression
of TFPI-2 gene in cancer cells are not well understood.
Cytosine hypermethylation at CpG dinucleotides in the
promoter of tumor suppressor genes represents a major
mechanism for gene inactivation in cancer. Methylation at
5' position of cytosine has been reported to alter or inter-
fere with the correct binding of transcription factors to tar-
get sequences overlapping CpG dinucleotides [11,12],
and it also has a positive effect to recruit methyl-CpG
binding activities that associate with histone deacetylases
and other chromtin-modifying elements that lead to a
transcriptionally silenced state. Many genes are hyper-
methylated at their CpG islands-containing promoters
and subsequently inactivate in human tumors of different
etiology [13].
TFPI-2 promoter exhibits typical features of a housekeep-
ing gene with a high GC-rich content (approximately
75%). It has a typical GC box known as binding site for
the transcription factor Sp1, and three transcription initi-
ation sites (one major initiation site and the two minor
initiation sites, but without canonical TATA and CAAT
boxes [8,14]. It also has a potential Kruppel-like factor 6
(KLF6) binding site by bioinformatics. As transcription
factors, KLF6 and Sp1 cooperatively transactivate the
endoglin promoter of collagen alpha1(I), uPA, TGF-
beta1, and TGF-beta receptor type 1 [15-17]. Direct phys-
ical interaction between Sp1 and KLF6 was documented
by coimmunoprecipitation, pull-down experiments, and
the GAL4 one-hybrid system, mapping the KLF6 interac-
tion to the C-terminal domain of Sp1 [15].
Breast cancer is the most common malignancy among
females. Hypermethylation of promoter CpG islands,
which is frequently observed in breast cancer [18-20], is
often associated with transcriptional silencing of the asso-
ciated gene. In this paper, we explored both genetic and
epigenetic mechanisms controlling TFPI-2 expression in
human breast cancer cells and the results indicated that
TFPI-2 expression could be silenced by promoter hyper-
methylation by inducing inactive chromatin structure and
decreasing KLF6 binding to its DNA binding sequence.
Results
Expression of TFPI-2 in breast cancer cells
Expression of TFPI-2 protein in human breast cancer cell
lines with different metastasis potential was examined by
western blotting. As shown in Figure 1a, TFPI-2 could not
be detected in highly invasive breast cancer cell line
(MDA-MB-435), while it was expressed in low invasive
breast cancer cell lines (MCF-7 and T47D). TFPI-2 mRNA
was detected by real-time PCR and the results were corre-
sponded with that of TFPI-2 protein expression (Figure
1b). These data indicated that the expression of TFPI-2
might be regulated at transcriptional level.
The critical region for TFPI-2 promoter activity in breast 
cancer cell lines
To determine if genetic variations contribute to the down
regulation of TFPI-2 in breast cancer cells, the potential
promoter region (from-1 436 to +75) of TFPI-2 was
amplified from various cell lines including normal
human umbilical vein endothelial cell (HUVEC), low and
high metastatic breast cancer cell lines. After sequencing,
several genetic variations were detected among breast can-
cer cell lines (p-1436MDA-MB-435: -1100 a to g, -1077 a
to c, -1072 a to t, -1059 a to g, -876 t to o, -859 t to c, -811
Expression of TFPI-2 in human breast cancer cells with differ- ent metastasis potential Figure 1
Expression of TFPI-2 in human breast cancer cells 
with different metastasis potential. (A). Western blot 
analysis of TFPI-2 protein expression. The HUVEC cell line 
was used as positive control and the protein levels of 
GAPDH were determined as control. (B). Quantitative real-
time PCR analysis of TFPI-2 mRNA levels. All expression lev-
els of TFPI-2 in breast cancer cell lines were normalized to 
the level of its expression in HUVEC. Lane 1: MDA-MB-435. 
Lane 2: T47D. Lane 3: MCF-7. Lane 4: HUVEC.BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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a to g, +13 a to g; p-1436MDA-MB-231: -1222 a to g, -876
t to o, -463 c to t; p-1436MCF-7: -1196 g to c, -735 c to g,
-702 c to t, -467 g to c; "o" represents deletion mutation),
while the sequence from HUVEC was consistent with
what Kamei S had reported (gene bank: AF217542) [14].
Except +13 a to g in MDA-MB-435, all genetic variations
lie in the distal region of TFPI-2 promoter. The constructs
of TFPI-2 promoter luciferase-reporter bearing respective
genetic variations were transiently transfected into breast
cancer cells and the luciferase activities were measured
according to the manufacture's instruction. As shown in
the Figure 2a, the luciferase activities of these constructs
showed only slight difference and were not consistent
with TFPI-2 expression pattern in these cell lines, indicat-
ing that the genetic variations located in the region from -
460 to -1142 had no apparent effects on its promoter
activities.
To find out the critical region of TFPI-2 promoter in breast
cancer cell lines, we constructed several deletion con-
structs (P-1436, P-1142, P-962, P-667, P-572, P-397 and
P-144) and transiently transfected them into MCF-7 cell
line. The construct containing -667 to -1142 showed
stronger luciferase activity, suggesting the activator/
enhancer were presence between -667 to -1142. The trans-
activation effects were suppressed by the construct con-
taining nucleotides -1142 to -1436, indicating that the
repressor/silencer located in this region. In addition, the
constructs -144 to -667 exhibited virtually the same luci-
ferase activity as the -1436 construct, suggesting that
nucleotides between -144 to +1 contain the sufficient pro-
moter sequence for the expression of human TFPI-2 gene
in breast cancer cell (Figure 2b). To further explore the
functional relevance of TFPI-2 promoter sequences within
-144 to +1, we generated linker-scan mutants in this
region. As shown in Figure 2c, the luciferase activities of
SM4 to SM7 were obviously decreased (P < 0.05), indicat-
ing -84 to -36 is critical for TFPI-2 promoter activity. Anal-
ysis of this essential region by MatInspector revealed four
most possible transcription binding sites including AP1,
AP2, KLF6 and SP1 [21]. In addition, the mutation SM5
and SM6 decreased the promoter activity most signifi-
cantly (P < 0.01) and this region contains the core matrix
of KLF6, indicating that KLF6 plays an important role in
the regulation of TFPI-2 in breast cancer cells.
KLF 6 can bind and transactivate the promoter of TFPI-2
We cotransfected p-144 promoter-luciferase constructs
with various amounts of KLF6 expression plasmids. As
shown in Figure 3a, the transcription activity of p-144
increased 3~5 folder than control accordance with the
increasing of KLF6. To further test whether KLF6 binds to
-48 ~ -72 region, we performed electrophoretic mobility
shift assays (EMSA) using the predicated KLF6 binding
site as probe with nuclear extracts prepared from breast
Analysis of TFPI-2 promoter Figure 2
Analysis of TFPI-2 promoter. (A) Breast cancer cell lines 
were transfected with promoter-luciferase plasmid cloned 
from different cell lines, bearing respective genetic mutation. 
The promoter from different cell line has nearly the same 
luciferase activity in both MDA-MB-435 and MCF-7 cell lines. 
Results are shown as mean ± SD. The apparent lower level 
of promoter activity in MDA-MB-435 cell was not statistically 
significant (p = 0.342>0.05). (B) Luciferase reporter gene 
constructs with 5'ends between nucleotides -1436 and -144 
and a common 3'end at +75 were transiently transfected into 
breast cancer cells. The minimal construct P-144 has the 
same luciferase activity as P-1436. (C) Linker-scan mutation 
analysis of TFPI-2 promoter -144 to +1 region. The fragment 
from -144 to the transcriptional start point (+1) of TFPI-2 
promoter were systematically replaced with an BamH I & 
Xba I polylinker (GGATCCTCTAGA), the resulting 
sequence were analyzed for not introducing new transcrip-
tion factor binding site by MatInspector [21]. SM1 indicate 
the promoter sequence from -12 to +1, and in turn every 12 
bases from -144 to -12 was indicated by SM12 to SM2. Then 
the luciferase promoter reporter plasmids were transfected 
into MDA-MB-435 cell line and the reported luciferase activ-
ity was measured. Results are shown as mean ± SD relative 
to the wild type (*p < 0.05; **p < 0.001).BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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cancer cells. As shown in Fig 3b, the probe formed one
specific band, consistent with an authentic KLF6 binding
motif (CCACCC) and antibodies to KLF6 produced super
shifted complexes. There was no difference of KLF6 bind-
ing capability between MDA-MB-435 and MCF-7 cell lines
(Figure 3c).
Effects of DNA hypermethylation on the expression of 
TFPI-2
The 8173 bp DNA fragment ranging from -3 564 to +4
609 of the human TFPI-2 gene was analyzed for CpG
islands using online program [22]. After setting the crite-
ria of length >200 nt, with an observed to expected CpG
dinucleotide ratio >0.6 and G+C continent >50%, two
CpG-rich islands were found (-254 to +374 and +395 to
+750). The methylation status of the first CpG islands,
encompassing -144 to +1, was determined by bisulfite
sequencing. As shown in Figure 4a, all CpG dinucleotides
in the region from -177 to +358, except -59 and -56 sites,
was methylated in MDA-MB-435 cells, while in MCF-7
cells, no methylation of CpG was. Together with the scan
mutation data, we concluded that the binding of KLF6
was affected by CpG methylation, resulting in silence of
TFPI-2 in MDA-MB-435 cell line. Treatment of MDA-MB-
435 with 5-aza-2'-deoxycitidine, the most commonly
used demethylation agent, obviously restored TFPI-2
expression in a concentration-dependent manner (Figure
4b, c), indicating that the down regulation of TFPI-2 in
breast cancer cells is related with DNA hypermethylation.
CpG hypermethylation diminished the binding of KLF6 to 
TFPI-2 promoter
To test the effects of CpG methylation on the binding of
KLF6, we carried out the competition experiment. In
detail, the formation of KLF6 and Kc complex was com-
peted with different concentration (50×, 100×, 200×) of
cold Kc, K6, mK6 and Kmute. As shown in Figure 5a, for-
mation of KLF6 complex was abrogated more effectively
by competition with K6-50× and Kc-50× than that by
competition with mK6-50× and Kmute-50×, indicating
the transcription activator KLF6 has higher affinity with
unmethylated probe than CpG methylated oligonucle-
otides, and the nucleotides C in the core matrix of KLF6
binding site was important to KLF6 binding for mutation
of C to T decreased the binding affinity obviously. In addi-
tion, we used in vivo ChIP assays to demonstrate the
effects of CpG methylation on KLF6 binding. KLF6 could
bind to TFPI-2 promoter within the CpG islands in MCF-
7 cells, for which the TFPI-2 promoter is unmethylated,
but not in MDA-MB-435 cells, for which this promoter is
methylated (Figure 5b). These data suggested that KLF6
could bind to CpG islands in TFPI-2 promoter and dimin-
ished by CpG methylation in its core sequence.
KLF6 can transactivate and binds to the promoter of TFPI-2 Figure 3
KLF6 can transactivate and binds to the promoter of 
TFPI-2. (A) The p-144 promoter-luciferase activity induced 
by cotransfection with various amount of KLF6 expression 
plasmids in MDA-MB-435 cells. The KLF6 cDNA was a gen-
erous gift of Scott Friedman and was cloned into PCDNA 3.0 
expression vector. (B) Both the predicted KLF6 binding 
sequence (K6) and the authentic KLF6 binding (Kc) [46] can 
form specific bands with nuclear extract (NE) from MCF-7 
cell lines. And the specific bands were supershifted by the 
antibody of KLF6. (C) No difference of K6 binding activity 
was found between MCF-7 and MDA-MB-435 cell lines. Lane 
1 to 6: NE from MCF-7; lane 7, 8: NE from MDA-MB-435. 
Lane 5, 7: 2.5 µg NE; lane 6, 8: 5 µg NE.BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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Discussion
Our study showed that human breast cancer cells exhib-
ited a differential pattern of TFPI-2 expression, with high
invasive breast cancer cells (MDA-MB-435) showing no
expression of TFPI-2 at all, while much higher levels of
TFPI-2 expression were observed in lower invasive MCF-7
and T47D. All three bands reacted with anti-TFPI-2 poly-
clone antibody were single-gene products with differential
glycosylation [23]. It had already been reported that TFPI-
2 had an anti-invasive effect that might be mediated via
inhibition of plasmin that activates proteases promoting
degradation of extracellular matrix and tumor invasion.
Several tumor cell lines were less invasive when they were
stably transfected with TFPI-2 [5-9]. These results suggest
that repression of TFPI-2 gene may be an important event
that contributes to breast cancer progression as well as its
malignant and invasive phenotype.
Despite the clonal origin of most tumors, their tremen-
dous heterogeneity suggests that cancer progression
springs from the combined forces of both genetic and epi-
genetic events, which produce variant clonal populations,
together with the selective pressures of the microenviron-
ment, which promote growth and, perhaps, dissemina-
tion of variants with a specific set of characteristics [24].
We hypothesized that both genetic variations and DNA
hypermethylation might contribute to the down regula-
tion of TFPI-2 during the progression of breast cancer. To
verify this hypothesis, we focused on two cell lines, MCF-
7, a hormone-sensitive and low invasive cell line that rep-
(A) The sequence of CpG islands in TFPI-2 promoter Figure 4
(A) The sequence of CpG islands in TFPI-2 promoter. The CpG dinucleoide detected by bisulfite modified sequence was indi-
cated in gray shadow. (B) The TFPI-2 gene promoter is highly methylated in MDA-MB-435 cells, whereas it is largely unmethyl-
ated in MCF-7 cells. For each cell type, the methylation status of 8 individual clones as determined by bisulfite sequencing 
analyses is shown in rows 1 to 8. The filled or open circles represent the methylated or unmethylated CpG sites, respectively. 
(C, D) MDA-MB-435 cells were seeded into 10 cm tissue culture dishes at an initial density of 33% confluence, allowed to 
attach over night, and then replaced with medium containing 1.25, 2.5 and 5 µM of AZA for 72 hour, then expression of TFPI-
2 was detected by western-blot (C) and real-time PCR (D).BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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resents early stage human breast cancer, and MDA-MB-
435 cell, which are hormone-insensitive and represent
late stage breast cancer [25].
It had already been reported that no sequence variations
were detected in any coding exon of TFPI-2 gene in blood
donors and apoplectic patients, while the promoter
CpG methylation blocked the binding of KLF6 to TFPI-2 promoter Figure 5
CpG methylation blocked the binding of KLF6 to TFPI-2 promoter. (A) CpG methylation in core matrix decreased 
the binding ability of KLF6 in vitro. Competition were used to determine the affinity of K6, Kc, methylated K6 (mK6) and 
muted K6 (Kmute). A 50- fold, 100-fold and 200-fold (50×, 100×, 200×) molar excess of cold K6, Kc, mK6 and Kmute cold 
probe were chased with labeled Kc. All the sequences were listed in table 1 (B) ChIP reveals that hypermethylation blocks 
KLF6 binding to the TFPI-2 promoter in vivo. Both CpG Unmethylated MCF-7 and methylated MDA-MB-435 cells were tested 
for binding of KLF6 by ChIP in vivo. Templates for PCR corresponded to the input used in the ChIP assay (input) and DNA 
obtained from immunoprecipitations performed in the absence (No antibody) or presence of anti KLF6-specific antibody.BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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region is relatively polymorphic [26]. We cloned the
potential promoter region (from-1 436 to +75) of TFPI-2
gene and found several genetic mutations among breast
cancer cell lines. However, these variations located in the
region from -1100 to -450 had no apparent effects on
their luciferase reporter activities. One possible explana-
tion as why the genetic alteration at a specific locus does
not have an impact on its transcriptional activity was the
distal region of TFPI-2 promoter where the point muta-
tion located was not critical for TFPI-2 promoter activity
[14,27]. The deletion and scan mutation of TFPI-2 pro-
moter support this idea.
Cancers often exhibit aberrant methylations at gene pro-
moter regions that is associated with loss of gene function
[28]. TFPI-2 promoter exhibits typical features of a house-
keeping gene [8,14]. Analysis with Methprimer revealed
that two complete CpG islands spanning promoter and
exon 1 and 2 [22]. CpG island hypermethylation has been
described in almost every tumor type including breast
cancer [13]. It had also been reported that DNMT inhibi-
tor restored expression of TFPI-2 in several cancer cell
lines [29-32]. Methylation at the 5' position of cytosine
has been reported to alter or interfere with the correct
binding of transcription factors to target sequences over-
lapping CpG dinucleotides [11,12], and it also recruit
methyl-CpG binding activities that associate with histone
deacetylases and other chromtin-modifying elements that
lead to a transcriptionally silenced state.
KLF6, a candidate tumor suppressor gene in prostate can-
cer [33], contains 283 aa and is present in many tissues,
including placenta, heart, lung, liver and pancreas. As an
activator of transcription, KLF6 interacts with the core
promoter element of a TATA box-less gene [34] and coop-
erate with other transcription factors in Kruppel-like fam-
ily, including SP1 and KLF4 [15]. It had already been well
documented that the promoter region of TFPI-2 has a high
GC-rich content (approximately 75%), with the presence
of typical GC boxes known as binding sites for the tran-
scription factor Sp1 [8,35-37]. After we found that there
were no difference of KLF6 binding between MDA-MB-
435 and MCF-7 cell (Fig 3c), we considered that the coop-
eration of KLF6 and SP1 might be affected by abnormal
hypermethylation in KLF6 binding site.
Treating the cell line MDA-MB-435 with Trichostatin A
(TSA) which is a histone deacetylase inhibitor alone (from
100 to 300 ng/ml) could not reactivate expression of TFPI-
2, but TSA could enhance the effects of methylase inhibi-
tor AZA (data not shown). The TSA insensitive compo-
nent of DNMT1 repression may be mediated by its
interaction with DNMT associated protein (DMAP1) [38].
These data indicated a cooperative model for histone
deacetylation and DNA methylation in maintaining the
silence of TFPI-2 in high invasive breast cancer cells.
Another question needed to be addressed is why the SP1
binding site in TFPI-2 promoter remains unmethylated in
high metastasis breast cancer cell. A possible proposal is
that Sp1 elements protect a CpG island from de novo
methylation, occurred in tumor genesis [39-41] and this
needs to be further investigated.
Conclusion
In the present work, we shown that: 1) expression of TFPI-
2 was repressed in highly invasive breast cancer cell lines;
2) the -84 ~ -36 region was critical for TFPI-2 promoter
activity and a KLF6 binding site existed in this region
which was abnormally hypermethylated in MDA-MB-
435; 3) The CpG methylation in the binding site of KLF-6
blocked the binding of KLF6 to TFPI-2 promoter, dimin-
ished the trans-activation of KLF6 on the expression of
TFPI-2 gene. On the basis of these findings, we conclude
that the down regulation of TFPI-2 in highly metastasis
breast cancer was due to the abnormal hypermethylation
in CpG dinucleotides of KLF-6 binding site.
Methods
Cell cultures and drug treatment
Human breast cancer cell lines MDA-MB-435, MDA-MB-
231, T47D and MCF-7 were purchased from American
Type Culture collection (ATCC, Manassas, VA), cultured
in DMEM with 5% CO2. Normal Human Umbilical Vein
Endothelial Cell (HUVEC, ATCC, Manassas, VA) were cul-
tured in Ham's F12K supplemented with 30% fetal bovine
serum (FBS) and kept at 37°C with 5% CO2. All material
used in cell culture were purchased from Gibco BRL, with
the exception of calf serum which was purchased from
PAA Laboratories (Linz, Austria). 5-aza-2'-deoxycitidine
(decitabine, AZA) was purchased from Sigma-Aldrich (St
Louis, MO, USA)
Western blot and quantitative real-time PCR analysis
Standard western blot and quantitative real-time PCR
analysis were used to analyze protein and RNA expression
respectively. Anti-TFPI-2 serum were obtained by immu-
nization of rabbit [42] and anti-GAPDH were purchased
from Kangchen (Shanghai, China). Primers targeting
TFPI-2 and GAPDH listed in Table 1, were designed using
Primer Express software (O-9 to O-12). The PCR reaction
was performed in triplicates using the SYBR Green Master
Mix (ABI, Warrington, UK) based assay in an ABI 7300
Real Time PCR System according to the manufacturer's
instructions.
Amplification of TFPI-2 promoter region and construction 
of 5' deletion mutants and linker scanning mutants
Genomic DNA was isolated with the genomic DNA isola-
tion kit (Beyotime, Jiangsu, China) according to the man-
ufacture's instruction. A 1.5 Kb fragment of the 5'-flankingBMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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region of TFPI-2 was amplified from various cell lines with
Super Taq DNA polymerase (Shenergy Biocolor, Shang-
hai, China) using the oligos O-1 and O-2 to create Kpn I
and Xho I restriction site. This Kpn I/Xho I fragment was
cloned into the plasmid PGL3-Basic (Promega, Charbon-
nières, France), named p-1436MDA-MB-435, p-
1436MDA-MB-231, p-1436MCF-7 and p-1436HUVEC
respectively. The 5' deletion constructs p-1142, p-962, p-
667, p-572, p-397 and p-144 were created by PCR using
the p-1436 HUVEC as template and O-2, O-3 to O-8 as
primers were listed in Table 1. The linker scanning
mutants of TFPI-2 promoter were created using PCR-
based technique in which consecutive 12-base-pair
stretches of wild-type TFPI-2 promoter sequence were
replaced with BamH I & Xba I polylinker (GGATC-
CTCTAGA). This technique has been described previously
[43,44]. Primers used were S1 to S12 and O-1, 2. All con-
structs were confirmed by automated sequencing per-
formed by United Gene Holding, LTD. (Shanghai,
China).
Transient transfection and reporter-luciferase assay
Cells were seeded into six-well plates at a concentration
sufficient to give 60–80% confluence on the day of trans-
fection, typically 4 × 105 cells/well, and cultured over-
night. All plasmids for transfection were isolated by
QIAGEN plasmid purification kit (QIAGEN, Germany).
Transient transfection by jetPEI Polyplus (Poly-plus trans-
fection, France) were performed according to the manu-
facture's instruction and phRL-CMV Vector (Promega,
Charbonnières, France) was used as transfection efficiency
control. 48 h after transfection, both firefly and Renilla
luciferase activities were measured using Dual-luciferase
reporter assay system (Promega, Charbonnières, France)
with Luminoskan TL plus Luminometer (Labsystem, Ger-
many) according to the manufacturer's protocol. The rel-
Table 1: Oligonucleotides
List Sequence
O-1 5'-TCAAGGTACCAGCTTCATACATGCTTGGTTGGGGT-3'
O-2 5'-GTATCTCGAGGGTGCAGGGGGTCGGGCG-3'
O-3 5'-TCGGGGTACCCCTTGGACTACGCAGGAATT-3'
O-4 5'-ACGGGGTACCCCTGGCCTAAGGATGGAAG-3'
O-5 5'-TCGGGGTACCCCATGTTGGCCAGGCTAGTC-3'
O-6 5'-ACGGGGTACCCCCAGCCAAAATGTTCTAATTCTT-3'
O-7 5'-ACGGGGTACCCCATTGCAACGAATCCCG-3'
O-8 5'-TCGGGGTACCCCTCTCCCTCTTACACAGTTTGC-3'
O-9 5' GCTGTGGAGGGAATGACAATAAC 3'
O-10 5' GCGAAGCTTTGGCATCTTCTTT 3'
O-11 5'-GGTGGTCTCCTCTGACTTCAACA-3'
O-12 5'-CAAAGTGGTCGTTGAGGGCA-3'
O-13 5'-GGTTTAATTTTTTAATTTGG-3'
O-14 5'-AAAAATTCTATCCCCTTCC-3'
S1 5'-ACGCTCGCCCCGCATAAAGCGGGCACCCGGGGATCCTCTAGAAGAAAGCCGCGCACCTC-3'
S2 5'-GGGGTCGGCCGGACGCTCGCCCCGCATAAAGGATCCTCTAGAGCCGCCTGGAGCAGAAA-3'
S3 5'-TCCGCCCCGGCGGGGGTCGGCCGGACGCTCGGATCCTCTAGAGCGGGCACCCGGGCCGC-3'
S4 5'-CACCCCTCAGGCTCCGCCCCGGCGGGGGTCGGATCCTCTAGAGCCCCGCATAAAGCGGG-3'
S5 5-'GCATGAATCAGCCACCCCTCAGGCTCCGCCGGATCCTCTAGAGGCCGGACGCTCGCCCC 3'
S6 5'-GACAGTCCCCGTGCATGAATCAGCCACCCCGGATCCTCTAGACCGGCGGGGGTCGGCCG-3'
S7 5'-GGGCGGCGGGGTGACAGTCCCCGTGCATGAGGATCCTCTAGATCAGGCTCCGCCCCGGC-3'
S8 5'-TTTGCAGCGCGGGGGCGGCGGGGTGACAGTGGATCCTCTAGAATCAGCCACCCCTCAGG-3'
S9 5'-CCTCTTACACAGTTTGCAGCGCGGGGGCGGGGATCCTCTAGACCCCGTGCATGAATCAG-3'
S10 5'-GGAATTCCTCTCCCTCTTACACAGTTTGCAGGATCCTCTAGACGGGGTGACAGTCCCCG-3'
S11 5'-TCAACTTGGCGGGGAATTCCTCTCCCTCTTGGATCCTCTAGAGCGCGGGGGCGGCGGGG-3'
S12 5'-AGGTTCAACTTTTCAACTTGGCGGGGAATTGGATCCTCTAGAACACAGTTTGCAGCGCG-3'
KcS 5-GAT CAG GTC ACC CAC AGG CCC-3
KcA 5-GGG CCT GTG GGT GAC CTG ATC-3
K6S 5-CCCTCAGGCTCCGCCCCGGCG-3
K6A 5-CGCCGGGGCGGAGCCTGAGGG-3
mKS 5-CCCTCAGGCTCC(CH3)GCCCCGGCG-3
mKA 5-CGCCGGGGC(CH3)GGAGCCTGAGGG-3
KmuteA 5-CCCTCAGGCTCTGCCCCGGCG-3
KmuteS 5-CGCCGGGGTGGAGCCTGAGGG-3
C1 5' GTGCATGAATCAGCCACC 3'
C2 5' AGCAGCAGAATCGACAGC 3'BMC Molecular Biology 2007, 8:110 http://www.biomedcentral.com/1471-2199/8/110
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ative luciferase units (RLU), which is the ratio of firefly's
activity to that of Renilla, were then obtained. Each trans-
fection was carried out in triplicate, and thus the mean
and standard deviations were determined.
Bisulfite modified sequence
Genomic DNA were isolated with the Genomic DNA iso-
lation Kit (Beyotime, Jiangsu, China) and bisulfite treat-
ment was carried out as described [45]. Briefly, genomic
DNA was sheared into 200 to 1000 bp fragments by ultra-
sonication, 2 µg of DNA was diluted into 50 µl, then dena-
turated for 10 minutes at 37°C with 5.5 µl of 2 M NaOH.
Then, 55 µl of freshly prepared hydroxyquinone (10 mM,
Sigma-Aldrich) and 520 µl of freshly prepared sodium
bisulfite (40.5%, pH = 5, Sigma-Aldrich) were added,
mixed, and then incubated under mineral oil at 50°C for
16 hr. Modified DNA was purified using DNA purification
resin according to the manufacturer (Shenergy Biocolor,
Shanghai, China,) and eluted into 100 µl of water. Modi-
fication was completed by NaOH (final concentration,
0.3 M) treatment for 10 min at room temperature, fol-
lowed by ethanol precipitation. DNA was resuspended in
water and used immediately or stored at -20°C. Modified
DNA was amplified with FastStarTaq DNA Polymerase
(Roche, Mannheim, Germany) by O-13 and O-14. The
PCR fragments amplified were gel-purified cloned using
pGEM-T vector system (Promega). Eight clones were
sequenced to assess the level of methylation in each CpG
site.
Electrophoretic mobility shift assays (EMSA)
Analysis of DNA-protein interactions was performed
using DIG Gel Shift Kit (Roche, Mannheim, Germany)
according to the manufacture's instructions. Briefly, the
double stranded oligonucleotides were 3'-end labeled
with DIG-11-ddUTP using terminal transferase. 50 fmol
labeled oligonucleotides were incubated with nuclear
extract, prepared using cellLytic™ NuCLEAR™ Extraction
Kit (Sigma), in binding buffer [20 mM HEPES (pH 7.4), 1
mM MgCl2, 10 µM ZnSO4, 20 mM KCl, 2% Ficoll, and 1
µg of poly (dI-dC)] for 20 min at 37°C. For competition
and supershift assay, the unlabeled oligonucleotides (cold
probe) and anti-KLF6 polyclonal antibody (SC-7185x,
Santa Cruz, CA, USA) were incubated for 5 min prior to
the addition of labeled oligonucleotide. 7% native poly-
acrylamide gel in 0.5 × TBE (Tris-borate-EDTA buffer) was
prepared and used for electrophoresis (in 0.5 × TBE) and
gel shift reactions. Blotting was performed using Biorad
electro-blotting system according to the manufacturer's
instructions. Chemiluminescence detection of DIG-
labeled DNA-protein complexes on nylon membranes
was detected using GSPD.
Chromatin Immunoprecipitation (ChIP) assay
ChIP assays were performed using Upstate ChIP Assay Kit
(Lake Placid, NY, USA) according to the manufacturer's
instructions. In brief, cells were fixed with 1% formalde-
hyde for 10 min at 37°C. After washing with cold-PBS,
cells were lysed in SDS lysis buffer, and sonicated to shear
DNA to an average fragment size of 500 bp. Anti-KLF6
antibody (SC-7185x, Santa Cruz, CA, USA) was added.
After overnight incubation at 4°C, immune complexes
were collected with salmon sperm DNA/protein agarose-
50% slurry (Upstate) for 1 h, and then extensively
washed. Samples were extracted with elution buffer (1%
SDS, 0.1 M NaHCO3), and heated at 65°C overnight to
reverse crosslinks. DNA was purified and used for PCR.
The primer sets (listed in Table 1) were designed to
encompass the potential KLF6 binding sites in TFPI-2
gene.
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